General Information of Drug (ID: DMX7DVH)

Drug Name
GSK163090 Drug Info
Synonyms
844903-58-8; GSK-163090; UNII-7XI927X82B; CHEMBL1631540; 7XI927X82B; 1-(3-(2-(4-(2-Methyl-5-quinolinyl)-1-piperazinyl)ethyl)phenyl)-2-imidazolidinone; 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone; 1-[3-[2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl]phenyl]-2-imidazolidinone; ANGUXJDGJCHGOG-UHFFFAOYSA-N; GSK 163090; SCHEMBL2881345; DTXSID30233480; EX-A1027; BCP16941; ZINC34451922; BDBM50333015; AKOS030526918; CS-5315; HY-14348
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Discontinued in Phase 2 [1]
Episode N.A. Discontinued in Phase 2 [1]
Major depressive disorder 6A70.3 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
11292933
CAS Number
CAS 844903-58-8
TTD Drug ID
DMX7DVH
VARIDT Drug ID
DR00731

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [3]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [4]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [5]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [6]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [7]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [8]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [9]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [10]
Treximet DMU54QB Migraine 8A80 Approved [2]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026154)
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
5 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
6 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
7 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
8 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
9 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
10 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)